Covance Appoints VP of Clinical Development Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Covance Appoints VP of Clinical Development Services



Covance reported that Barry J. Goldstein, MD, PhD, has joined its clinical development services business as vice-president and global therapeutic area head of the expanded cardiovascular, metabolic, endocrine, and renal unit.  In this new role, Goldstein will join the medical & scientific affairs leadership team and will be based in Princeton, NJ.
 
Goldstein joins Covance from Merck where he served as vice-president in clinical research and therapeutic area head for diabetes and endocrinology, since 2008.  In this role, he managed Merck’s Phase II-IV clinical development team for a large portfolio including diabetes, obesity, osteoporosis, and women’s health.  His responsibilities included strategic input to proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, responses to payer inquiries, lifecycle management activities, as well as pharmacovigilance and post-marketing studies. In addition to his biopharmaceutical industry experience, Goldstein’s medical career includes serving as director, division of endocrinology, diabetes & metabolic diseases, Jefferson Medical College at Thomas Jefferson University in Philadelphia from 1992 to 2008.  His most recent academic roles include professor of medicine, biochemistry and molecular pharmacology at Jefferson from 1997 to 2008.
 
Source: Covance

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here